Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.34 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018094 | 0.81 | TSHR (0.38) | ALDH1A1KMT2AKDM4E | |
| SCHEMBL3014721 | 0.80 | CHRM2 (0.38) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL15355170 | 0.77 | MAPT (0.40) | ALDH1A1LMNAKMT2AMAPTFKBP1A | |
| SCHEMBL765596 | 0.77 | MAPT (0.40) | ALDH1A1LMNAKMT2AMAPTFKBP1A | |
| SCHEMBL3019979 | 0.77 | ALDH1A1 (0.37) | ALDH1A1LMNAKMT2AMAPTFKBP1A | |
| SCHEMBL3017836 | 0.73 | MAPT (0.42) | ALDH1A1MAPTFKBP1AKDM4ESMN1; SMN2 | |
| SCHEMBL3019089 | 0.72 | MAPT (0.36) | ALDH1A1LMNAKMT2AMAPTKDM4E | |
| SCHEMBL3022604 | 0.72 | ALDH1A1 (0.34) | ALDH1A1LMNAKMT2AMAPTFKBP1A | |
| SCHEMBL3016989 | 0.72 | ALDH1A1 (0.34) | ALDH1A1LMNAKMT2AMAPTFKBP1A | |
| SCHEMBL3023499 | 0.71 | MAPT (0.38) | ALDH1A1LMNAKMT2AMAPTFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204438-A1 | METHOD FOR PRODUCING TEDA DERIVATIVES | BASF SE (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-2197882-A2 | METHOD FOR PRODUCING TEDA DERIVATIVES | Basf Se (DE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009030649-A2 | METHOD FOR PRODUCING TEDA DERIVATIVES | BASF SE (DE) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204438-A1 | METHOD FOR PRODUCING TEDA DERIVATIVES | TES, TRRAP, NAAA | ALDH1A1 720/4885LMNA 2940/4885KMT2A 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.